DNLI vs PRTA
DNLI: Denali Therapeutics is a clinical-stage biopharmaceutical company developing a proprietary platform to transport large-molecule medicines across the blood-brain barrier for the treatment of neurodegenerative diseases and rare disorders. PRTA: A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through proprietary CYTOPE® intracellular delivery technology, in partnership with major pharma.
Side-by-side fundamentals
| Metric | DNLI | PRTA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $23.64 | $8.44 | |
| Market cap as of 2026-07-23 | $3.7B | $458M | |
| PEG as of 2026-07-23 | -1.05 | -0.09 | DNLI lower |
| Net margin as of 2026-07-23 | -36.5% | -260.9% | DNLI higher |
| Operating margin as of 2026-07-23 | -49.7% | -205.4% | DNLI higher |
| ROE as of 2026-07-23 | -50.1% | -49.9% | PRTA higher |
| ROA as of 2026-07-23 | -44.2% | -42.3% | PRTA higher |
| Debt / equity as of 2026-07-23 | 0.01 | 0.00 | PRTA lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -58.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -43.6% | |
| Beta as of 2026-07-23 | 0.99 | -0.38 | |
| 1-year return as of 2026-07-22 close | +72.3% | +29.2% | DNLI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.